Venture Capital
Longwood Fund
Longwood Fund backs early-stage and high-growth companies, typically pre-profit, from Boston, MA. It states a focus on healthcare & life sciences.
Stated investment criteria
What Longwood Fund says it buys
Read from Longwood Fund’s own website in August 2026. This is what the firm says it buys, not what anyone has recorded it buying, and figures are shown in the currency the firm itself used - nothing here is converted. Every line links to the page it was read from.
| People listed on its team page | 81 |
Source
A stated mandate is a firm’s description of itself and was true of the page on the day it was read; firms widen and narrow what they will look at without updating the site. The team figure counts the people the firm shows on one team page, so it is a floor rather than a headcount: firms that split their team across tabs or load it in pages will read low. Nothing here is a commitment by Longwood Fund to consider any particular business, and nothing on this page is represented as being for sale.
Regulatory record
How Longwood Fund is registered
From this firm's Form ADV, the annual filing every registered and exempt investment adviser makes to the SEC.
| Adviser status | Exempt reporting adviser |
| Regulatory assets under management | Not reported by an ERA |
| Private funds advised | 12 · $456m gross |
| SEC adviser number | CRD 281220 |
An exempt reporting adviser is not required to report regulatory assets under management, so the blank above means the question was not asked rather than that the answer is unknown. Where a figure exists it is the gross asset value of the private funds the firm advises, which is a different and usually larger measure.
Portfolio
Disclosed holdings
Companies Longwood Fund lists on its own website. No investment years are published.
| Company | Invested | Years held | Recorded transaction |
|---|---|---|---|
| 25+ portfolio companies in biotech | — | — | — |
| Aavantgarde | — | — | — |
| Aavantgardebio | — | — | — |
| Alnara | — | — | — |
| Archer | — | — | — |
| Avenzo | — | — | — |
| Bbot | — | — | — |
| Be Bio | — | — | — |
| Bebiopharma | — | — | — |
| Bicycletherapeutics | — | — | — |
| Bridgebio | — | — | — |
| Calithera Biosciences | — | — | — |
| Carbon | — | — | — |
| Channel Medsystems | — | — | — |
| Coultreon | — | — | — |
| Coultreon Biopharma | — | — | — |
| Crystalys | — | — | — |
| Dem | — | — | — |
| Dembiopharma | — | — | — |
| Engrail | — | — | — |
| Evommune | — | — | — |
| Grail | — | — | — |
| Illuminoss | — | — | — |
| Immunitas Therapeutics | — | — | — |
| Industry Events | — | — | — |
| Interius | — | — | — |
| Interiusbio | — | — | — |
| Kalvista | — | — | — |
| Kalvista Pharmaceuticals | — | — | — |
| Khartis | — | — | — |
| Khartis Therapeutics | — | — | — |
| Lassentherapeutics | — | — | — |
| Mediar | — | — | — |
| Millendo Therapeutics | — | — | — |
| Mitobridge | — | — | — |
| Neomorph | — | — | — |
| Newleos | — | — | — |
| Photys | — | — | — |
| Progentos | — | — | — |
| Ptc Therapeutics | — | — | — |
| Ptcbio | — | — | — |
| Pulmocide | — | — | — |
| Pyxisoncology | — | — | — |
| Rectify | — | — | — |
| Rectifypharma | — | — | — |
| Sidewinder | — | — | — |
| Sidewinderbio | — | — | — |
| Sitryx | — | — | — |
| Solu | — | — | — |
| Solutherapeutics | — | — | — |
| Tscan | — | — | — |
| Verastem | — | — | — |
| Weaver | — | — | — |
| Werewolf | — | — | — |
| Xaira | — | — | — |
| Xylocor | — | — | — |
| oncology | — | — | — |
Compiled from Longwood Fund’s published portfolio page. Where a recorded transaction is shown, that company was the target of a reported deal and has most likely already been realised. Nothing here is represented as being for sale.
Valuation context
Transaction values in Healthcare & Life Sciences
What companies have actually sold for in healthcare & life sciences, across 1,263 recorded transactions.
The full healthcare & life sciences picture - most active acquirers, recent transactions and every investor in the sector.
For owners
Own a healthcare & life sciences business?
The investors on this page acquire companies like yours. A confidential valuation costs nothing, commits you to nothing, and nobody is told you asked.
Request a confidential valuationFor investors
Is this Longwood Fund?
Claim this profile to correct anything wrong and tell us what you are looking for. We will send matching opportunities as they arise.
Claim or correct this profileTargeted buyer search
Which hundred of these would actually buy your business?
A researched shortlist with a verified deal-team contact for each, and the reason it is on the list. Fixed fee, from $1,450 - or we make the approach for you and hand you the conversations.
Comparable investors
Similar mandates
Other venture capital investors active in healthcare & life sciences.